Over the last 3 decades there have been substantial improvements in treatments aimed at
reducing cardiovascular (CV) events. As these treatments have been developed, there have …

Atherosclerotic plaque assessment has become a crucial element in the examination of
cardiovascular diseases. Plaque may exhibit progression and could become unstable if not …

Aims Despite the effects of statins in reducing cardiovascular events and slowing
progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains …

Cardiac computed tomography (CT) was initially developed as a non-invasive diagnostic
tool to detect and quantify coronary stenosis. Thanks to the rapid technological …

Background and Purpose: Atrial fibrillation is a risk factor for dementia, and oral
anticoagulant use is associated with a decreased risk of dementia in patients with atrial …

Atherosclerotic plaque results from a complex interplay between lipid deposition,
inflammatory changes, cell migration and arterial wall injury. Over the past two decades …

Warfarin has been utilized for decades as an effective anticoagulant in patients with a history
of strong risk factors for venous thromboembolism (VTE). Established adverse effects …

Chronic kidney disease (CKD) is associated with a higher prevalence of vascular
calcification (VC) and cardiovascular disease. VC in CKD patients showed different …

Aims Though statin therapy is known to slow coronary atherosclerosis progression and
reduce cardiovascular (CV) events, significant CV risk still remains. In the REDUCE-IT study …

Non-vitamin K antagonist oral anticoagulants (NOACs) should be the preferred
anticoagulant strategy for preventing ischemic stroke in patients with atrial fibrillation (AF) at …